medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2024, Number 05

<< Back Next >>

Ginecol Obstet Mex 2024; 92 (05)

Identification of the “Spike” protein in umbilical cord blood of newborns from mothers vaccinated against SARS-CoV-2 during pregnancy

Malfavón FM, Vázquez CEE, Borboa-Olivares HJ, Flores MMÁ, Santiago SL

Language: Spanish
References: 34
Page: 189-197
PDF size: 219.26 Kb.


ABSTRACT

Objective: Identification of the presence of SARS-CoV-2 Spike protein antibodies in cord blood of newborns following maternal COVID-19 vaccination during pregnancy.
Materials and Methods: Cross-sectional study in vaccinated women during pregnancy who had a cord blood sample taken during the surgical procedure (Vaginal birth/Cesarean section) to measure spike protein antibodies.
Results: We registered 219 patients in the study: five types of vaccines, from two different platforms, were tested: Pfizer®, Moderna®, AstraZeneca®, J&J/Janssen® and Sputnik®. The levels of antibodies were greater in those patients vaccinated with Moderna ® and Sputnik®. Through a Cox regression we made a predictive model where we observed that there are no differences in the number of antibodies generated after the first and second vaccine dose.
Conclusions: Prenatal vaccination against COVID-19 induces a strong maternal humoral response that is effectively transferred to the fetus, even with a single dose.


REFERENCES

  1. Rasmussen AS, Collen FK, Horton JP, Jamieson DJ. CoronavirusDisease 2019 (COVID-19) Vaccines and Pregnancy.What Obstetricians Need to Know. Obstet Gynecol 2021;137 (3): 408-414. doi: 10.1097/AOG.0000000000004290

  2. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternalto neonatal transfer of antibodies against SARS-CoV-2 andBNT162b2 mRNA COVID-19 vaccine. J Clin Invest 2021;131;(13): e150319. doi: 10.1172/JCI150319

  3. Secretaria de Salud. Informe semanal de notificacion inmediatade muerte materna; 2020. https://www.gob.mx/cms/uploads/attachment/file/601780/MM_2020_SE51.pdf

  4. Secretaria de Salud. Informe Semanal de NotificaciónInmediata de Muerte Materna; 2021. https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/15_Manual_Muertes_Maternas_Lineamientos.pdf

  5. Woodworth KR, Olsen EO, Neelam V, et al. Birth and InfantOutcomes Following Laboratory-Confirmed SARS-CoV-2Infection in Pregnancy — SET-NET, 16 Jurisdictions, March29–October 14, 2020. MMWR Morb Mortal Wkly Rep 2020;

  6. 69 (44): 1635-1640. doi: 10.15585/mmwr.mm6944e26. Dubey P, Reddy SY, Manuel S, Dwivedi AK. Maternal andneonatal characteristics and outcomes among COVID-19infected women: An updated systematic review and metaanalysis.Eu J Obstet Gynecol Reprodu Biol 2020; 252:490-501. doi: 10.1016/j.ejogrb.2020.07.034

  7. Stafford IA, Parchem JG, Sibai BM. The coronavirus disease2019 vaccine in pregnancy: risks, benefits, and recommendations.Am J Obstet Gynecol 2021;224 (5): 484-495. doi:10.1016/j.ajog.2021.01.022

  8. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNACovid-19 Vaccines and Risk of Spontaneous Abortion.N Engl J Med 2021; 385 (16): 1533-1535. doi: 10.1056/NEJMc2113891

  9. Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccinationduring pregnancy: coverage and safety. Am J ObstetGynecol 2022; 226 (2): 236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007

  10. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findingsof mRNA Covid-19 Vaccine Safety in Pregnant Persons.N Engl J Med 2021; 384 (24): 2273-2282. doi: 10.1056/NEJMoa2104983

  11. Lipkind H, Vazquez-Benitez G, DeSilva M. Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Smallfor-Gestational-Age at Birth — Eight Integrated Health CareOrganizations, United States, December 15, 2020–July 22,2021. Morbidity and Mortality Weekly Report (MMWR).https://www.cdc.gov/mmwr/volumes/71/wr/mm7101e1.htm?s_cid=mm7101e1_w

  12. Centers for Disease Control and Prevention. Pregnancyor Breastfeeding; 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html

  13. E. Riley L, Beigi R, Jameison D. Vaccinating Pregnant andLactating Patients Against COVID-19. ACOG. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactatingpatients-against-covid-19

  14. SMFM: Provider Considerations for Engaging in COVID-19Vaccine Counseling With Pregnant and Lactating Patients.https://s3.amazonaws.com/cdn.smfm.org/media/3282/Provider_Considerations_for_Engaging_in_COVID_Vaccination_Considerations_12-20-21_%28final%29.pdf

  15. Atyeo CG, Shook LL, Brigida S, et al. Maternal ImmuneResponse and Placental Antibody Transfer after COVID-19Vaccination across Trimester and Platforms. Nat Commun2022; 13 (1): 3571. doi: 10.1038/s41467-022-31169-8.

  16. Male V. SARS-CoV-2 infection and COVID-19 vaccination inpregnancy. Nat Rev Immunol 2022; 22 (5): 277-282. doi:10.1038/s41577-022-00703-6

  17. Maternal Immunization: ACOG Committee Opinion, Number741. Obstet Gynecol 2018; 131 (6): e214-e217. doi:10.1097/AOG.0000000000002662

  18. Naranbhai V, Garcia-Beltran WF, Chang CC, et al. ComparativeImmunogenicity and Effectiveness of mRNA-1273,BNT162b2 and Ad26.COV2.S COVID-19 Vaccines. J InfectDis 2022; 225 (7): 1141-1150. doi: 10.1093/infdis/jiab593.

  19. Tada T, Zhou H, Samanovic MI, et al. Comparison of NeutralizingAntibody Titers Elicited by mRNA and AdenoviralVector Vaccine against SARS-CoV-2 Variants. Front Immunol

  20. 2022; 13: 797589. doi: 10.3389/fimmu.2022.79758920. Barouch DH, Stephenson KE, Sadoff J, et al. DurableHumoral and Cellular Immune Responses 8 Months afterAd26.COV2.S Vaccination. N Engl J Med 2021; 385 (10):951-953. doi: 10.1056/NEJMc2108829

  21. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.Svaccine against SARS-CoV-2 variants in humans. Nature2021; 596 (7871): 268-272. doi: 10.1038/s41586-021-03681-2

  22. ACOG. COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19- vaccination-considerations-for-obstetric-gynecologic-care (2021).

  23. Society for Maternal Fetal Medicine. Provider Considerationsfor Engaging in COVID Vaccination Considerations.https://s3.amazonaws.com/cdn.smfm.org/media/3201/Provider_Considerations_for_Engaging_i n_COVID_Vaccination_Considerations_10-26-21_%28final%29.pdf (2021).

  24. CDC. COVID-19 Vaccine Booster Shots. https://www.cdc.gov/coronavirus/2019- ncov/vaccines/booster-shot.html (2021).

  25. Updated Recommendations for Use of Tetanus Toxoid,Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine(Tdap) in Pregnant Women and Persons Who Have orAnticipate Having Close Contact with an Infant Aged <12Months --- Advisory Committee on Immunization Practices(ACIP), 2011. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6041a4.htm

  26. Eberhardt CS, Blanchard-Rohner G, Lemaître B, et al.Maternal Immunization Earlier in Pregnancy MaximizesAntibody Transfer and Expected Infant SeropositivityAgainst Pertussis. Clin Infect Dis 2016; 62 (7): 829-836.doi: 10.1093/cid/ciw027

  27. Horiya M, Hisano M, Iwasaki Y, et al. Efficacy of DoubleVaccination With the 2009 Pandemic Influenza A (H1N1)Vaccine During Pregnancy. Obstet Gynecol 2011; 118 (4):887-894. doi: 10.1097/AOG.0b013e31822e5c02

  28. Yamaguchi K, Hisano M, Isojima S, et al. Relationship ofTh1/Th2 cell balance with the immune response to influenzavaccine during pregnancy. J Med Virol 2009; 81 (11):1923-1928. doi: 10.1002/jmv.21620

  29. Blanchard-Rohner G, Meier S, Bel M, et al. InfluenzaVaccination Given at Least 2 Weeks Before Delivery toPregnant Women Facilitates Transmission of SeroprotectiveInfluenza-specific Antibodies to the Newborn. PediatrInfect Dis J 2013; 32 (12): 1374-1380. doi: 10.1097/01.inf.0000437066.40840.c4

  30. Cuningham W, Geard N, Fielding JE, et al. Optimal timingof influenza vaccine during pregnancy: A systematic reviewand meta‐analysis. Influenza Other Respi Viruses 2019; 13(5): 438-452. doi: 10.1111/irv.12649

  31. Saji F. Dynamics of immunoglobulins at the feto-maternalinterface. Reviews of Reproduction. 1999;4(2):81-89. doi:10.1530/ror.0.0040081

  32. Ciapponi A, Bardach A, Mazzoni A, et al. Safety of componentsand platforms of COVID-19 vaccines considered foruse in pregnancy: A rapid review. Vaccine. 2021; 39 (40):5891-5908. doi: 10.1016/j.vaccine.2021.08.034

  33. Mayo Clinic. Comparación de Las Diferencias Entre Las VacunasContra La COVID-19.; 2022. https://www.mayoclinic.org/es/diseases-conditions/comparing-vaccines

  34. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al.Safety and efficacy of an rAd26 and rAd5 vector-basedheterologous prime-boost COVID-19 vaccine: an interimanalysis of a randomised controlled phase 3 trial in Russia.Lancet 2021; 397 (10275): 671-681. doi: 10.1016/S0140-6736(21)00234-8




2020     |     www.medigraphic.com